Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2009

View Archived Issues

Ad2/HIF-1alpha/VP16 not effective in treating intermittent claudication

Studies show benefit of preprocedure atorvastatin loading in patients undergoing PCI

Increased malapposition seen with paclitaxel-eluting stent in acute myocardial infarction patients

Preliminary results from phase I/II study of BL-1040 myocardial implant presented

Bayer describes novel substituted tricyclic compounds for cancer treatment

Novel cytotoxic xanthone compounds claimed by Bristol-Myers Squibb

Roche claims novel NK3 receptor antagonists

Sanofi-aventis and Mitsubishi Tanabe Pharma claim novel tau protein kinase inhibitors

Novel compounds for the treatment of diabetes discovered by Kyorin and ActivX

Merck KGaA launches Lodotra in Germany

BioMS receives positive safety review for phase III multiple sclerosis trial

Osprey initiates phase Ib trial in IgA nephropathy

Phase II study reveals activity of OZ1 gene therapy in HIV patients

BioVex commences OncoVEX phase III metastatic melanoma trial

BioSante launches Elestrin in the U.S.

SC-599 well tolerated, induces protective immune responses in phase II study

Strativa provides product pipeline update for ODFS

Tobira Therapeutics initiates proof-of-concept study with TAK-652 for HIV

FDA grants orphan drug designation for Paclical in ovarian cancer

Jubilant and Orion sign drug discovery partnership

ImmuneRegen and University of Rochester to examine Homspera in lethal radiation exposure

Oxygen and Hospira sign development and commercial supply agreement for Oxycyte

Anesthetic/sedative CNS-7056 begins phase II

Sanofi-aventis to acquire BiPar Sciences

EVT-302 shows no benefit as aid to smoking cessation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...